Jean K Ho1, Daniel A Nation1. 1. Department of Psychology,University of Southern California,Los Angeles,California.
Abstract
OBJECTIVES: The present study investigated the independent and synergistic effects of amyloid beta (Aβ1-42) and phosphorylated tau (Ptau) pathologies on neuropsychological profiles and trajectories in cognitively normal older adults. METHODS: Alzheimer's Disease Neuroimaging Initiative participants identified as cognitively normal at baseline underwent longitudinal assessment (N=518; 0, 12, 24, 36 months), baseline lumbar puncture and follow-up cognitive exams. Cerebral spinal fluid (CSF) biomarker profiles (Aβ-Ptau-, Aβ+Ptau-, Aβ-Ptau+, Aβ+Ptau+) were compared on baseline profiles and trajectories for memory (Rey Auditory Verbal Learning Test), attention/executive function (Trail Making Test, A and B), language (Animal Fluency, Vegetable Fluency, Boston Naming Test) and processing speed (Digit Symbol) using multilevel models. RESULTS: The Aβ+Ptau+ group exhibited significantly worse baseline performance on tests of memory and executive function relative to the Aβ-Ptau+ and Aβ-Ptau- groups. The Aβ+Ptau- group fell between the Aβ+Ptau+ participants and the Aβ-Ptau- and Aβ-Ptau+ groups on all three cognitive domains and exhibited worse baseline executive function. The Aβ-Ptau+ group performed worse than Aβ-Ptau- participants on processing speed. Over 36-month follow-up, the Aβ+Ptau+ group exhibited the greatest declines in memory and semantic fluency compared to all other groups. CONCLUSIONS: Cognitively normal older adults with both Aβ and Ptau pathology exhibited the weakest profile, marked by the worst memory decline compared to the other groups. Other subtle changes in this group included declines in executive function and semantic fluency. Those with Ptau pathology alone showed slowed processing speed, and those with Aβ pathology alone showed worse attention and executive function compared to biomarker negative participants. (JINS, 2018, 24, 693-702).
OBJECTIVES: The present study investigated the independent and synergistic effects of amyloid beta (Aβ1-42) and phosphorylated tau (Ptau) pathologies on neuropsychological profiles and trajectories in cognitively normal older adults. METHODS:Alzheimer's Disease Neuroimaging Initiative participants identified as cognitively normal at baseline underwent longitudinal assessment (N=518; 0, 12, 24, 36 months), baseline lumbar puncture and follow-up cognitive exams. Cerebral spinal fluid (CSF) biomarker profiles (Aβ-Ptau-, Aβ+Ptau-, Aβ-Ptau+, Aβ+Ptau+) were compared on baseline profiles and trajectories for memory (Rey Auditory Verbal Learning Test), attention/executive function (Trail Making Test, A and B), language (Animal Fluency, Vegetable Fluency, Boston Naming Test) and processing speed (Digit Symbol) using multilevel models. RESULTS: The Aβ+Ptau+ group exhibited significantly worse baseline performance on tests of memory and executive function relative to the Aβ-Ptau+ and Aβ-Ptau- groups. The Aβ+Ptau- group fell between the Aβ+Ptau+participants and the Aβ-Ptau- and Aβ-Ptau+ groups on all three cognitive domains and exhibited worse baseline executive function. The Aβ-Ptau+ group performed worse than Aβ-Ptau- participants on processing speed. Over 36-month follow-up, the Aβ+Ptau+ group exhibited the greatest declines in memory and semantic fluency compared to all other groups. CONCLUSIONS: Cognitively normal older adults with both Aβ and Ptau pathology exhibited the weakest profile, marked by the worst memory decline compared to the other groups. Other subtle changes in this group included declines in executive function and semantic fluency. Those with Ptau pathology alone showed slowed processing speed, and those with Aβ pathology alone showed worse attention and executive function compared to biomarker negative participants. (JINS, 2018, 24, 693-702).
Entities:
Keywords:
Alzheimer’s disease; Amyloid beta; Biomarkers; Cognition; Memory; Tau
Authors: Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow Journal: Nat Rev Drug Discov Date: 2010-07 Impact factor: 84.694
Authors: Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan Journal: Lancet Neurol Date: 2013-09-04 Impact factor: 44.182
Authors: C M Hulette; K A Welsh-Bohmer; M G Murray; A M Saunders; D C Mash; L M McIntyre Journal: J Neuropathol Exp Neurol Date: 1998-12 Impact factor: 3.685
Authors: Kathryn V Papp; Elizabeth C Mormino; Rebecca E Amariglio; Catherine Munro; Alex Dagley; Aaron P Schultz; Keith A Johnson; Reisa A Sperling; Dorene M Rentz Journal: Neuropsychology Date: 2015-11-23 Impact factor: 3.295
Authors: Elizabeth C Mormino; Kathryn V Papp; Dorene M Rentz; Aaron P Schultz; Molly LaPoint; Rebecca Amariglio; Bernard Hanseeuw; Gad A Marshall; Trey Hedden; Keith A Johnson; Reisa A Sperling Journal: JAMA Neurol Date: 2016-10-01 Impact factor: 18.302
Authors: Daniel E Gustavson; Matthew S Panizzon; Carol E Franz; Chandra A Reynolds; Robin P Corley; John K Hewitt; Michael J Lyons; William S Kremen; Naomi P Friedman Journal: J Exp Psychol Gen Date: 2019-03-21
Authors: Cutter A Lindbergh; Kaitlin B Casaletto; Adam M Staffaroni; Renaud La Joie; Leonardo Iaccarino; Lauren Edwards; Elena Tsoy; Fanny Elahi; Samantha M Walters; Devyn Cotter; Michelle You; Alexandra C Apple; Breton Asken; John Neuhaus; Jessica E Rexach; Kevin J Wojta; Gil Rabinovici; Joel H Kramer Journal: Neuropsychology Date: 2020-10-08 Impact factor: 3.295
Authors: Jordan Stiver; Adam M Staffaroni; Samantha M Walters; Michelle Y You; Kaitlin B Casaletto; Sabrina J Erlhoff; Katherine L Possin; Sladjana Lukic; Renaud La Joie; Gil D Rabinovici; Molly E Zimmerman; Maria Luisa Gorno-Tempini; Joel H Kramer Journal: Clin Neuropsychol Date: 2021-03-26 Impact factor: 4.373
Authors: Laura A Rabin; Crystal G Guayara-Quinn; Caroline O Nester; Liam Ellis; Nadia Paré Journal: Neuropsychol Dev Cogn B Aging Neuropsychol Cogn Date: 2021-02-23
Authors: Kirsty Lu; Jennifer M Nicholas; Sarah-Naomi James; Christopher A Lane; Thomas D Parker; Ashvini Keshavan; Sarah E Keuss; Sarah M Buchanan; Heidi Murray-Smith; David M Cash; Carole H Sudre; Ian B Malone; William Coath; Andrew Wong; Susie M D Henley; Nick C Fox; Marcus Richards; Jonathan M Schott; Sebastian J Crutch Journal: Alzheimers Dement (Amst) Date: 2020-08-10
Authors: Nicholas Bott; Erica N Madero; Jordan Glenn; Alexander Lange; John Anderson; Doug Newton; Adam Brennan; Elizabeth A Buffalo; Dorene Rentz; Stuart Zola Journal: J Med Internet Res Date: 2018-07-24 Impact factor: 5.428